Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Reed

Urology Burien, WA Medical Doctor

NPI 1912945791 CMS profile 177237

16259 Sylvester Rd Sw, 303, Burien, WA 98166

Open in the dashboard

General payments

$8,690

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Reed of Burien, WA is reported in the CMS Open Payments database as having received $8,690 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $362 2
2023 General $4,250 1
2022 General $25 2
2021 General $758 29
2020 General $729 34
2019 General $2,566 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Reed
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Reed were reported at $362. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Reed Urology median Middle half National median
2019 $2,566 $480 $147–$1,201 $163
2020 $729 $246 $87–$645 $114
2021 $758 $358 $111–$1,000 $132
2022 $25 $476 $143–$1,263 $149
2023 $4,250 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $362 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Verathon Inc. $4,500 2 payments
  2. Boston Scientific Corporation $1,077 12 payments
  3. Ferring Pharmaceuticals Inc. $425 10 payments
  4. Astellas Pharma US Inc $392 18 payments
  5. Janssen Biotech, Inc. $274 13 payments
  6. Amgen Inc. $255 7 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $241 11 payments
  8. Dendreon Pharmaceuticals LLC $240 12 payments
  9. AbbVie, Inc. $213 10 payments
  10. Janssen Scientific Affairs, LLC $211 6 payments
  11. Other $862 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,500 2 payments
  2. Food and Beverage $3,484 133 payments
  3. Travel and Lodging $470 3 payments
  4. Education $237 6 payments
Products named General payments · program years 2019–2025
  1. NPD Clinical Study & Bronchoscope $4,250 1 payment
  2. AMS $672 5 payments
  3. XTANDI $527 25 payments
  4. FIRMAGON $401 8 payments
  5. ERLEADA $373 18 payments
  6. NPD Clinical Study $250 1 payment
  7. PROVENGE $240 12 payments
  8. Xofigo $194 9 payments
  9. Nubeqa $176 8 payments
  10. ADVANCE $166 3 payments
  11. Other $1,588 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

221

Median for Urology: 1,053

Drug cost

$3,572

Median for Urology: $101,464

Branded share of claims

0%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Solifenacin Succinate Generic 77 $1,969
Tamsulosin Hcl Generic 100 $745
Silodosin Generic 16 $684
Finasteride Generic 16 $125
Ciprofloxacin Hcl Generic 12 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$11,251

Medicare's payments for the services billed

Medicare patients

103

Average age 75

Services billed

136

24 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Chronic kidney disease 34%
Diabetes 32%
Ischemic heart disease 27%
Atrial fibrillation 18%
COPD 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record